跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HDAC6
首页
药物
HDAC6
HDAC6
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
INHIBITING HISTONE DEACETYLASE 6 (HDAC6)
EP 4504191 A4
申请人: EIKONIZO THERAPEUTICS INC
优先权: 2022
CN
EP
US
WO
11 件公开
2-ISOINDOL-1,3,4-OXADIAZOLE DERIVATIVES USEFUL AS HDAC6 INHIBITORS
EP 4034536 A1
申请人: TAKEDA PHARMACEUTICALS CO
优先权: 2019
CN
EP
US
WO
8 件公开
3-(2-(HETEROARYL)-PYRIDIN-4-YL)-5-(TRIFLUOROMETHYL)-1,2,4-OXADIAZOLE DERIVATIVES AS HDAC6 INHIBITORS
EP 3980416 B1
申请人: ORYZON GENOMICS SA
优先权: 2019
CN
EP
US
WO
6 件公开
HDAC6 INHIBITORS AND USES THEREOF
EP 4003319 A4
申请人: EIKONIZO THERAPEUTICS INC
优先权: 2019
CN
EP
US
WO
6 件公开
US 2024174616 A1
申请人: EIKONIZO THERAPEUTICS INC
优先权: 2021
US
WO
3 件公开
US 9586973 B2
申请人: UNIV GENT
优先权: 2015
US
US 20250179065 A1
申请人: EIKONIZO THERAPEUTICS INC
优先权: 2023
US
HDAC6 INHIBITORS AND IMAGING AGENTS
EP 4397656 A2
申请人: MASSACHUSETTS GEN HOSPITAL
优先权: 2017
CN
EP
US
6 件公开
QUINAZOLINE DERIVATIVES USEFUL AS SELECTIVE HDAC6 INHIBITORS
EP 4161908 A1
申请人: ANNJI PHARM CO LTD
优先权: 2020
CN
EP
US
WO
4 件公开
NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS
US 2023286970 A1
申请人: ITALFARMACO SPA
优先权: 2020
CN
EP
US
WO
4 件公开
A COMBINATION COMPRISING A SPECIFIC HDAC6 INHIBITOR AND AT LEAST ONE CTLA4 CHECKPOINT INHIBITOR
EP 4326259 A1
申请人: ITALFARMACO SPA
优先权: 2021
CN
EP
US
WO
4 件公开
DIFLUORO- AND TRIFLUORO-ACETYL HYDRAZIDES AS SELECTIVE HDAC6 INHIBITORS
EP 4568949 A1
申请人: ITALFARMACO SPA
优先权: 2022
CN
EP
US
WO
4 件公开
HETEROCYCLIC COMPOUNDS AS SELECTIVE HDAC6 INHIBITORS
EP 4680602 A1
申请人: MIRALINC PHARMA INC
优先权: 2023
CN
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈